AMIDEBIO, LLC
Long-acting solution-stable glucagon analogs for treating severe persistent hyperinsulinism
- Sector
- Biotech
- Headquarters
- Louisville, CO
- Founded
- 2009
- Latest Form D
- $764K, Nov 2017
- Total capital
- $11M
- Federal grants
- $8.2M
- 10 awards · 2017–2025
- Rank in peer group#70 of 514
- Private capital raised
- $2.7M
- 7 Form D · last Nov 2017
- 108 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 26 pending · first 2015
- Rank in peer group#71 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH)$999K
- Federal grantHealth and Human S · Phase II · Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH)$930K
- Federal grantHealth and Human S · Phase II · Long-acting Stable Glucagons for Treatment of Hyperinsulinism$1.4M
- Federal grantHealth and Human S · Phase II · Long-acting Stable Glucagons for Treatment of Hyperinsulinism$2.7M
- Federal grantHealth and Human S · Phase I · Novel Glucose Responsive Insulin for Improved Treatment of Diabetes$116K
- Federal grantHealth and Human S · Phase I · Novel Glucose Responsive Insulin for Improved Treatment of Diabetes$184K
- Federal grantHealth and Human S · Phase II · Stable Glucagon for Treatment of Hyperinsulinism$817K
- Private capital raisedForm D · SEC · 7th filing$764K
- Private capital raisedForm D · SEC · 6th filing$144K
- Private capital raisedForm D · SEC · 5th filing$279K
- Private capital raisedForm D · SEC · 4th filing$400K
- Private capital raisedForm D · SEC · 3rd filing$300K
- Private capital raisedForm D · SEC · 2nd filing$575K
- Private capital raisedForm D · SEC · 1st filing$275K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · Stable Glucagon for Treatment of Hyperinsulinism$740K
- Federal grantHealth and Human S · Phase I · Stable Glucagon for Treatment of Hyperinsulinism$207K
- Federal grantHealth and Human S · Phase I · Stable Glucagon for Treatment of Hyperinsulinism$131K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#70 · top 14%
- Granted patents#71 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Michael StowellResearcherExecutive Officer, DirectorLinked by 3 patents
- David C. BarkerDirectorNamed in SEC Form D filings
- David P. BrunelDirectorNamed in SEC Form D filings
- Gregory C. AbbottDirectorNamed in SEC Form D filings
- Mikhail PlamExecutive Officer, DirectorNamed in SEC Form D filings
- Niles UtlautDirectorNamed in SEC Form D filings
Show all 8 people
- Ruel MercureDirectorNamed in SEC Form D filings
- Vincent P. MihalikDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 31- PendingGlucose-responsive Insulin Analogs And Methods Of Use ThereofUSPTOApplication 19340410
- PendingGlucose-responsive Insulin Analogs And Methods Of Use ThereofUSPTOApplication 18618780
- GrantedGlucagon Analogs And Methods Of Use ThereofUSPTOUS 11,179,444
Show all 31 patent records
- Glucose-responsive Insulin Analogs And Methods Of Use ThereofJan 22, 2026 · Application 19340410Pending
- Glucose-responsive Insulin Analogs And Methods Of Use ThereofOct 17, 2024 · Application 18618780Pending
- Glucagon Analogs And Methods Of Use ThereofNov 23, 2021 · US 11,179,444Granted
- Glucose-responsive Insulin Analogs And Methods Of Use ThereofSep 16, 2021 · Application 17213765Pending
- Methods For Producing Peptides And Uses ThereofMar 21, 2019 · Application 16084934Pending
- Methods, Compositions, Diagnostics And Assays For The Treatment Of Alzheimer's DiseaseMar 19, 2019 · US 10,233,222Granted
- Efficient Production Of PeptidesJul 5, 2018 · Application 15815370Pending
- Chemically And Thermodynamically Stable Insulin Analogues And Improved Methods For Their ProductionDec 28, 2017 · Application 15689140Pending
- Efficient Production Of PeptidesJul 21, 2016 · Application 15002259Pending
- Chemically And Thermodynamically Stable Insulin Analogues And Improved Methods For Their ProductionJun 16, 2016 · Application 14846063Pending
- Efficient Production Of PeptidesFeb 23, 2016 · US 9,266,934Granted
- Modified Peptides And ProteinsDec 31, 2015 · Application 14752461Pending
- Chemically And Thermodynamically Stable Insulin Analogues And Improved Methods For Their ProductionOct 20, 2015 · US 9,163,073Granted
- Chemically And Thermodynamically Stable Insulin Analogues And Improved Methods For Their ProductionSep 17, 2015 · Application 14657804Pending
- Chemically And Thermodynamically Stable Insulin Analogues And Improved Methods For Their ProductionApr 14, 2015 · US 9,006,176Granted
- Modified Peptides And ProteinsOct 16, 2014 · Application 14219792Pending
- Chemically And Thermodynamically Stable Insulin Analogues And Improved Methods For Their ProductionApplication PCTUS2014034411Pending
- Methods, Compositions, Diagnostics and Assays for the Treatment of Alzheimer's DiseaseApplication 61974320Pending
- Chemically and Thermodynamically Stable Insulin Analogues and Improved Methods for their ProductionApplication 61813174Pending
- Chemically And Thermodynamically Stable Insulin Analogues And Improved Methods For Their ProductionApplication PCTUS2012060459Pending
- Dual Glucagon Insulin Agonists And Methods Of Use ThereofApplication PCTUS2026017150Pending
- Dual Glucagon Insulin Agonists And Methods Of Use ThereofApplication 63765334Pending
- Deuterated PeptidesApplication PCTUS2011062733Pending
- Modified Peptides And ProteinsApplication PCTUS2011044407Pending
- Methods For Producing Peptides And Uses ThereofApplication PCTUS2017022806Pending
- Glucose-responsive Insulin Analogs And Methods Of Use ThereofApplication 16499932Pending
- Glucose-responsive Insulin Analogs And Methods Of Use ThereofApplication 62480859Pending
- Glucagon Analogs And Methods Of Use ThereofApplication 62348101Pending
- Methods For Producing Peptides And Uses ThereofApplication 62309381Pending
- Glucagon Analogs And Methods Of Use ThereofApplication PCTUS2017036808Pending
- Glucose-responsive Insulin Analogs And Methods Of Use ThereofApplication PCTUS2018025070Pending
Related companies, and why
- ASTROCYTE PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- Soteria Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- NATURA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Calder Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- CRIMSON BIOPHARM INCSimilar federal contract value in Biotech · null in contracts
- TOSK, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .